Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention

Expert Review of Hematology

Volumn 3, Issue 5, 2010, Pages 559-566

  Skogen, Bjørn ^a,b   Killie, Mette Kjær ^a   Kjeldsen Kragh, Jens ^c,d   Ahlen, Maria Therese ^a   Tiller, Heidi ^a   Stuge, Tor B ^a,b   Husebekk, Anne ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

anti HPA 1a antibodies; fetal and neonatal alloimmune thrombocytopenia; FNAIT; pregnancy; thrombocytopenia

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN IIIA; HLA DR ANTIGEN; IMMUNOGLOBULIN; RHESUS D ANTIBODY; RHESUS D ANTIGEN; STEROID; THROMBOCYTE ANTIGEN;

ANTIBODY BLOOD LEVEL; BLEEDING; BLOOD GROUP TYPING; BRAIN HEMORRHAGE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFIDENTIALITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FETUS ECHOGRAPHY; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH EDUCATION; HIGH RISK PREGNANCY; HUMAN; IMMUNIZATION; INFORMED CONSENT; MASS SCREENING; MORTALITY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN HEMOLYTIC DISEASE; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; REPRODUCTIVE HISTORY; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; THROMBOCYTE TRANSFUSION;

ANTIGENS, HUMAN PLATELET; BIOLOGICAL MARKERS; CHILD; FEMALE; FETUS; HUMANS; INFANT; INFANT, NEWBORN; INTRACRANIAL HEMORRHAGES; ISOANTIBODIES; NEONATAL SCREENING; PREGNANCY; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 78049431669     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.49     Document Type: Review

References (63)

1. Newman P, Derbes R, Aster R. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 83, 1778-1781 (1989). (Pubitemid 19124140)
2. Kabir-Salmani M, Fukuda MN, Kanai-Azuma M et al. The membrane-spanning domain of CD98 heavy chain promotes aVb3 integrin signals in human extravillous throphoblasts. Mol. Endocrinol. 22, 707-715 (2008).
3. Kjeldsen-Kragh J, Killie MK, Tomter G et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 110, 833-839 (2007). (Pubitemid 47267418)
4. Kaplan C, Daffos F, Forestier F, Morel MC, Chesnel N, Tchernia G. Current trends in neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Platelet Immunology: Fundamental and Clinical Aspects. Kaplan-Gouet C, Schlegel N, Salmon Ch, McGregor J (Eds). Colloque INSERM/John Libbey Eurotext Ltd, Paris, France 267-278 (1991).
5. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust. NZ J. Obstet. Gynaecol. 41, 45-55 (2001).
6. Mueller-Eckhardt C, Grubert A, Weisheit M et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 333, 363-366 (1989). (Pubitemid 19103082)
7. Muller JY, Reznikoff-Etievant MF, Patereau C, Dangu C, Chesnel N. Neonatal alloimmune thrombopenia. Clinical and biological study of 84 cases. Presse Med. 14, 83-86 (1985).
8. + T cells. Blood 113, 3838-3844 (2009).
9. LAbbe D, Tremblay L, Filion M et al. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Hum. Immunol. 34, 107-114 (1992).
10. Williamson LM, Hackett G, Rennie J et al. The natural history of fetomaternal alloimmunization to the platelet-specifc antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 92, 2280-2287 (1998). (Pubitemid 28452968)
11. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 93, 870-877 (2008). (Pubitemid 351821723)
12. Ahlen MT, Killie MK, Husebekk A, Kjeldsen-Kragh J, Olsson ML, Skogen B. The development of severe anti-HPA 1a-related neonatal alloimmune thrombocytopenia is infuenced by the maternal ABO type. Blood 110, 623-623 (2007).
13. Bussel JB, Zacharoulis S, Kramer K et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr. Blood Cancer 45, 176-183 (2005). (Pubitemid 40993584)
14. Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev. 22, 33-52 (2008). (Pubitemid 351193026)
15. Tiller H, Killie MK, Skogen B, Oian P, Husebekk A. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG 116, 594-598 (2009).
16. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N. Engl. J. Med. 20, 1463-1466 (1993). (Pubitemid 23335892)
17. Turner ML, Bessos H, Fagge T et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 45, 1945-1956 (2005). (Pubitemid 43971423)
18. Uhrynowska M, Niznikowska-Marks M, Zupanska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur. J. Haematol. 64, 42-46 (2000). (Pubitemid 30055542)
19. Bassler D, Greinacher A, Okascharoen C et al. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion 48, 92-98 (2008).
20. Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst. Rev. CD004226 (2005).
21. Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 114, 588-595 (2007). (Pubitemid 46587959)
22. Gruel Y, Boizard B, Daffos F, Forestier F, Caen J, Wautier JL. Determination of platelet antigens and glycoproteins in the human fetus. Blood 68, 488-492 (1986). (Pubitemid 16050673)
23. Giovangrandi Y, Daffos F, Kaplan C, Forestier F, Mac AJ, Moirot M. Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia. Lancet 336, 310 (1990). (Pubitemid 20229151)
24. Murphy MF, Metcalfe P, Waters AH, Ord J, Hambley H, Nicolaides K. Antenatal management of severe feto-maternal alloimmune thrombocytopenia: HLA incompatibility may affect responses to fetal platelet transfusions. Blood 81, 2174-2179 (1993). (Pubitemid 23106735)
25. Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia. Vox Sang. 85, 326-327 (2003). (Pubitemid 37522608)
26. Jocelyn LJ, Casiro OG. Neurodevelopmental outcome of term infants with intraventricular hemorrhage. Am. J. Dis. Child. 146, 194-197 (1992).
27. Mao C, Guo J, Chituwo BM. Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants. J. Trop. Pediatr. 45, 237-240 (1999).
28. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang. 84, 318-325 (2003). (Pubitemid 36702338)
29. Dale ST, Coleman LT. Neonatal alloimmune thrombocytopenia: antenatal and postnatal imaging fndings in the pediatric brain. AJNR Am. J. Neuroradiol. 23, 1457-1465 (2002).
30. Ghevaert C, Campbell K, Walton J et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 47, 901-910 (2007). (Pubitemid 46669006)
31. Bonacossa IA, Jocelyn LJ. Alloimmune thrombocytopenia of the newborn: neurodevelopmental sequelae. Am. J. Perinatol. 13, 211-215 (1996).
32. Cota F, Zuppa AA, Luciano R et al. A severe case of intracranial hemorrhage due to alloimmune thrombocytopenia. J. Matern. Fetal. Neonatal. Med. 21, 852-854 (2008).
33. Govaert P, Bridger J, Wigglesworth J. Nature of the brain lesion in fetal allo-immune thrombocytopenia. Dev. Med. Child. Neurol. 37, 485-495 (1995).
34. Herman J, Jumbelic M, Ancona R, Kickler T. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am. J. Pediatr. Hematol. Oncol. 8, 312-317 (1986). (Pubitemid 17229764)
35. Lester RB 3rd, Sty J. Prenatal diagnosis of cystic CNS lesions in neonatal isoimmune thrombocytopenia. J. Ultrasound Med. 6, 479-481 (1987).
36. Morales WJ, Stroup M. Intracranial hemorrhage in utero due to isoimmune neonatal thrombocytopenia. Obstet. Gynecol. 65, 20S-21S (1985). (Pubitemid 15133773)
37. Póvoa AM, Ramalho C, Machado AP, Matias A, Montenegro N. Congenital posthemorrhagic hydrocephalus: a case of fetomaternal alloimmune thrombocytopenia. Fetal Diagn. Ther. 22, 321-324 (2007). (Pubitemid 47267788)
38. Kaplan C, Daffos F, Forestier F et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 72, 340-343 (1988). (Pubitemid 19066961)
39. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N. Engl. J. Med. 337, 22-26 (1997).
40. Khouzami AN, Kickler TS, Callan NA, Shumway JB, Perlman EJ, Blakemore KJ. Devastating sequelae of alloimmune thrombocytopenia: an entity that deserves more attention. J. Matern. Fetal Med. 5, 137-141 (1996). (Pubitemid 26193809)
41. Kroll H, Kiefel V, Giers G et al. Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia. Transfus. Med. 4, 293-296 (1994).
42. Lindemann R, Svenningsen L, Kjeldsen-Kragh J, Stiris T, Killie M, Husebekk A. Three special cases of pregnancy outcome to refect about. Tidsskr. Nor. Laegeforen. 9, 2244-2246 (2004).
43. Groves AM, Clough V, Stevens R. Neonatal alloimmune thrombocytopenia may be less severe in a subsequent pregnancy. Pediatr. Hematol. Oncol. 20, 393-398 (2003). (Pubitemid 36869795)
44. Goyenaga M, Fromont P, Muller JY, Valentin N. A HPA-1a negative woman immunized against HPA-1a antigen by platelet transfusion gave birth to a healthy HPA-1a positive child after disparition of the anti-HPA 1a at the end of pregnancy. A case report. Presented at: 7th European Symposium on platelet, granulocyte and red cell immunology. Lago Maggiore, Italy, 11-14 April 2002.
45. Birchall JE, Murphy MF, Kaplan C, Kroll H; European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br. J. Haematol. 122, 275-288 (2003).
46. Gaddipati S, Berkowitz RL, Lembet AA, Lapinski R, McFarland JG, Bussel JB. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am. J. Obstet. Gynecol. 185, 976-980 (2001). (Pubitemid 32980548)
47. Silver RM, Porter TF, Branch DW, Esplin MS, Scott JR. Neonatal alloimmune thrombocytopenia: antenatal management. Am. J. Obstet. Gynecol. 182, 1233-1238 (2000). (Pubitemid 30353317)
48. Ghevaert C, Campbell K, Stafford P et al. HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia. Transfusion 47, 1296-1305 (2007). (Pubitemid 46934325)
49. Bertrand G, Martageix C, Jallu V, Vitry F, Kaplan C. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J. Thromb. Haemost. 4, 628-637 (2006).
50. Jægtvik S, Husebekk A, Aune B, Øian P, Dahl LB, Skogen B. Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG 107, 691-694 (2000). (Pubitemid 30242867)
51. Wu S, Maslanka K, Gorski J. An integrin polymorphism that defnes reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J. Immunol. 158, 3221-3226 (1997). (Pubitemid 127484037)
52. Maslanka K, Yassai M, Gorski J. Molecular identifcation of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J. Clin. Invest. 98, 1802-1808 (1996). (Pubitemid 26359197)
53. Jackson DJ, Murphy MF, Soothill PW, Lucas GF, Elson CJ, Kumpel BM. Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism. Clin. Exp. Immunol 142, 92-102 (2005).
54. Sukati H, Bessos H, Barker RN, Urbaniak SJ. Characterization of the alloreactive helper T-cell response to the platelet membrane glycoprotein IIIa (integrin-p3) in human platelet antigen-1a alloimmunized human platelet antigen-1b 1b women. Transfusion 45, 1165-1177 (2005). (Pubitemid 40935017)
55. Anani Sarab G, Moss M, Barker RN, Urbaniak SJ. Naturally processed peptides spanning the HPA-1a polymorphism are effciently generated and displayed from platelet glycoprotein by HLA-DRB3*0101-positive antigen-presenting cells. Blood 114, 1954-1957 (2009).
56. Rayment R, Kooij TW, Zhang W et al Evidence for the specifcity for platelet HPA-1a alloepitope and the presenting HLA-DR52a of diverse antigen-specifc helper T cell clones from alloimmunized mothers. J. Immunol. 183, 677-686 (2009).
57. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat. Rev. Drug Discov. 8, 645-660 (2009).
58. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull. World Health Organ. 86, 317-319 (2008). (Pubitemid 351521860)
59. Murphy MF, Williamson LM. Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK national screening committee. Br. J. Haematol. 111, 726-732 (2000).
60. Chaoying M, Junwu G, Chituwo BM. Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants. J. Trop. Pediatr. 45, 237-240 (1999). (Pubitemid 29385260)
61. Tiller H, Chen P, Skogen B et al. Administration of anti-platelet antibodies prevents the anti-platelet immune response and bleeding complications of neonatal immune thrombocytopenia in a murine model. Blood 114, 97-97 (2009).
62. Koelewijn JM, de Haas M, Vrijkotte TG, van der Schoot CE, Bonsel GJ. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 116, 1307-1314 (2009).
63. Skogen B, Husebekk A, Killie MK, Kjeldsen-Kragh J. Neonatal alloimmune thrombocytopenia is not what it was. A lesson learned from from a large prospective screening and intervention program. Scand. J. Immunol. 70, 531-534 (2009).